Aldosterone inhibition reduces the risk of sudden cardiac death in patients with heart failure

Kishlay Anand, Aryan N. Mooss, Syed M. Mobiuddin

Research output: Contribution to journalReview article

17 Citations (Scopus)

Abstract

Sudden cardiac death (SCD) accounts for over 450,000 deaths annually in the USA. Sudden death is estimated to account for approximately 50% of all deaths from cardiovascular causes. Total cardiac mortality has decreased from 728,115 in 1989 to 719,456 in 1999 but the percentage of deaths that are sudden has actually increased from 38% to 47%. Prevention of SCD in patients with risk factors is a high priority for public health professionals. Aldosterone has been shown to be associated with myocardial inflammation, endothelial dysfunction and fibrosis. There is evidence from clinical trials suggesting the role of aldosterone inhibition in prevention of SCD. We reviewed the potential mechanisms and discuss the clinical implications of Randomised ALdactone Evaluation Study (RALES) and Eplerenone Neurohormonal Efficacy and Survival Study (EPHESUS). The use of aldosterone receptor blockers had an overall effect of 21% risk reduction in SCD. Appropriate monitoring and counselling is essential while using either of the aldosterone inhibitors.

Original languageEnglish
Pages (from-to)15-19
Number of pages5
JournalJRAAS - Journal of the Renin-Angiotensin-Aldosterone System
Volume7
Issue number1
DOIs
StatePublished - Mar 2006

Fingerprint

Sudden Cardiac Death
Aldosterone
Heart Failure
Sudden Death
Mineralocorticoid Receptors
Spironolactone
Risk Reduction Behavior
Counseling
Cause of Death
Fibrosis
Public Health
Clinical Trials
Inflammation
Survival
Mortality
Inhibition (Psychology)

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology

Cite this

Aldosterone inhibition reduces the risk of sudden cardiac death in patients with heart failure. / Anand, Kishlay; Mooss, Aryan N.; Mobiuddin, Syed M.

In: JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, Vol. 7, No. 1, 03.2006, p. 15-19.

Research output: Contribution to journalReview article

@article{ee7395bcc61d49c493ca8a8a92847544,
title = "Aldosterone inhibition reduces the risk of sudden cardiac death in patients with heart failure",
abstract = "Sudden cardiac death (SCD) accounts for over 450,000 deaths annually in the USA. Sudden death is estimated to account for approximately 50{\%} of all deaths from cardiovascular causes. Total cardiac mortality has decreased from 728,115 in 1989 to 719,456 in 1999 but the percentage of deaths that are sudden has actually increased from 38{\%} to 47{\%}. Prevention of SCD in patients with risk factors is a high priority for public health professionals. Aldosterone has been shown to be associated with myocardial inflammation, endothelial dysfunction and fibrosis. There is evidence from clinical trials suggesting the role of aldosterone inhibition in prevention of SCD. We reviewed the potential mechanisms and discuss the clinical implications of Randomised ALdactone Evaluation Study (RALES) and Eplerenone Neurohormonal Efficacy and Survival Study (EPHESUS). The use of aldosterone receptor blockers had an overall effect of 21{\%} risk reduction in SCD. Appropriate monitoring and counselling is essential while using either of the aldosterone inhibitors.",
author = "Kishlay Anand and Mooss, {Aryan N.} and Mobiuddin, {Syed M.}",
year = "2006",
month = "3",
doi = "10.3317/jraas.2006.001",
language = "English",
volume = "7",
pages = "15--19",
journal = "JRAAS - Journal of the Renin-Angiotensin-Aldosterone System",
issn = "1470-3203",
publisher = "SAGE Publications Ltd",
number = "1",

}

TY - JOUR

T1 - Aldosterone inhibition reduces the risk of sudden cardiac death in patients with heart failure

AU - Anand, Kishlay

AU - Mooss, Aryan N.

AU - Mobiuddin, Syed M.

PY - 2006/3

Y1 - 2006/3

N2 - Sudden cardiac death (SCD) accounts for over 450,000 deaths annually in the USA. Sudden death is estimated to account for approximately 50% of all deaths from cardiovascular causes. Total cardiac mortality has decreased from 728,115 in 1989 to 719,456 in 1999 but the percentage of deaths that are sudden has actually increased from 38% to 47%. Prevention of SCD in patients with risk factors is a high priority for public health professionals. Aldosterone has been shown to be associated with myocardial inflammation, endothelial dysfunction and fibrosis. There is evidence from clinical trials suggesting the role of aldosterone inhibition in prevention of SCD. We reviewed the potential mechanisms and discuss the clinical implications of Randomised ALdactone Evaluation Study (RALES) and Eplerenone Neurohormonal Efficacy and Survival Study (EPHESUS). The use of aldosterone receptor blockers had an overall effect of 21% risk reduction in SCD. Appropriate monitoring and counselling is essential while using either of the aldosterone inhibitors.

AB - Sudden cardiac death (SCD) accounts for over 450,000 deaths annually in the USA. Sudden death is estimated to account for approximately 50% of all deaths from cardiovascular causes. Total cardiac mortality has decreased from 728,115 in 1989 to 719,456 in 1999 but the percentage of deaths that are sudden has actually increased from 38% to 47%. Prevention of SCD in patients with risk factors is a high priority for public health professionals. Aldosterone has been shown to be associated with myocardial inflammation, endothelial dysfunction and fibrosis. There is evidence from clinical trials suggesting the role of aldosterone inhibition in prevention of SCD. We reviewed the potential mechanisms and discuss the clinical implications of Randomised ALdactone Evaluation Study (RALES) and Eplerenone Neurohormonal Efficacy and Survival Study (EPHESUS). The use of aldosterone receptor blockers had an overall effect of 21% risk reduction in SCD. Appropriate monitoring and counselling is essential while using either of the aldosterone inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=33745120159&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745120159&partnerID=8YFLogxK

U2 - 10.3317/jraas.2006.001

DO - 10.3317/jraas.2006.001

M3 - Review article

VL - 7

SP - 15

EP - 19

JO - JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

JF - JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

SN - 1470-3203

IS - 1

ER -